News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Governor Shapiro Secures Historic $3.5 Billion Investment from Eli Lilly to Build Pharmaceutical Manufacturing Facility in Lehigh County
Lilly’s investment is the largest by a life sciences company in Pennsylvania's history.
Four Penn Medicine Studies Named Among Nation’s Top 10 Clinical Research Advances
The Clinical Research Forum’s Top 10 Clinical Research Achievement Awards honor outstanding accomplishments in clinical research.
CarboWells Wins the 2026 Y-Prize Competition
The winning idea is based on technology developed by Shu Yang, PhD.
Penn Medicine and CHOP Faculty Make the TIME100 Health List for CRISPR Gene Therapy Breakthrough
Two doctors were recognized by TIME as pioneers in healthcare for successfully treating KJ Muldoon.
Penn Received $7.8 Million from ARPA-H to Advance Lymphatic Imaging and AI-Driven Disease Detection
The project is led by Maxim Itkin, MD, Professor of Radiology at Penn Medicine and the director of Penn’s Center for Lymphatic Disorders.
T Cells Targeting Misformed Proteins to Treat Neurodegenerative and Muscular Diseases
By targeting disease-specific proteins, this antigen-specific immunotherapy aims to selectively eliminate damaged cells, potentially offering a more precise and effective treatment approach.
Multiple Penn Affiliated Startups are Finalists for Awards at Life Science PA’s Annual Awards Dinner and Showcase
Each year, Life Sciences PA hosts a celebration to honor the innovation and commitment members have made to the life sciences industry.
REGENXBIO Announces Positive Long-Term Data for Gene Therapy RGX-202 for Duchenne Muscular Dystrophy
REGENXBIO was co-founded by James Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine.
European Commission Expands Approval of Sobi’s Aspaveli® for Rare Kidney Diseases
Aspaveli ® is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally.
GEMMA Biotherapeutic Announces Clinical Trial Authorization for New Gene Therapy Treatment
GEMMA announced that its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil.